The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Topical tacrolimus for atopic dermatitis
Open accessAbstract
BACKGROUND: Atopic dermatitis (AD) (or atopic eczema) is a chronic inflammatory skin condition that affects children and adults and has an important impact on quality of life. Topical corticosteroids (TCS) are the first-line therapy for this condition; however, they can be associated with significant adverse effects when used chronically. Tacrolimus ointment (in its 2 manufactured strengths of 0.1% and 0.03%) might be an alternative treatment. Tacrolimus, together with pimecrolimus, are drugs called topical calcineurin inhibitors (TCIs). OBJECTIVES: To assess the efficacy and safety of topical tacrolimus for moderate and severe atopic dermatitis compared with other active treatments. SEARCH METHODS: We searched the following databases up to 3 June 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (Issue 5, 2015), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), and the Global Resource of Eczema Trials (GREAT database). We searched six trials registers and checked the bibliographies of included studies for further references to relevant trials. We contacted specialists in the field for unpublished data.A separate search for adverse effects of topical tacrolimus was undertaken in MEDLINE and EMBASE on 30 July 2013. We also scrutinised the U.S. Food and Drug Administration (FDA) websites for adverse effects information. SELECTION CRITERIA: All randomised controlled trials (RCTs) of participants with moderate to severe atopic dermatitis (both children and adults) using topical tacrolimus at any dose, course duration, and follow-up time compared with other active treatments. DATA COLLECTION AND ANALYSIS: Two authors independently screened and examined the full text of selected studies for compliance with eligibility criteria, risk of bias, and data extraction. Our three prespecified primary outcomes were physician's assessment, participant's self-assessment of improvement, and adverse effects. Our secondary outcomes included assessment of improvement of the disease by validated or objective measures, such as SCORAD (SCORing Atopic Dermatitis), the EASI (Eczema Area and Severity Index), and BSA (Body Surface Area) scores. MAIN RESULTS: We included 20 studies, with 5885 participants. The variability of drug doses, outcomes, and follow-up periods made it difficult to carry out meta-analyses.A single trial showed that tacrolimus 0.1% was better than low-potency TCS by the physician's assessment (risk ratio (RR) 3.09, 95% confidence interval (CI) 2.14 to 4.45, 1 study, n = 371, moderate-quality evidence). It was also marginally better than low-potency TCS on face and neck areas and moderate-potency TCS on the trunk and extremities by the physician's assessment (RR 1.32, 95% CI 1.17 to 1.49, 1 study, n = 972, moderate level of evidence) and for some of the secondary outcomes. Compared with pimecrolimus 1%, people treated with tacrolimus were almost twice as likely to improve by the physician's assessment (RR 1.80, 95% CI 1.34 to 2.42, 2 studies, n = 506, moderate quality of evidence). Compared with the lower concentration of 0.03%, the tacrolimus 0.1% formulation reduced the risk of not having an improvement by 18% as evaluated by the physician's assessment (RR 0.82, 95% CI 0.72 to 0.92, 6 studies, n = 1640, high-quality evidence). Tacrolimus 0.1% compared with moderate-to-potent TCS showed no difference by the physician's assessment, and 2 secondary outcomes (1 study, 377 participants) and a marginal benefit favouring tacrolimus 0.1% was found by the participant's assessment (RR 1.21, 95% CI 1.13 to 1.29, 1 study, n = 974, low quality of evidence) and SCORAD.Based on data from 2 trials, tacrolimus 0.03% was superior to mild TCS for the physician's assessment (RR 2.58, 95% CI 1.96 to 3.38, 2 studies, n = 790, moderate-quality evidence) and the participant's self-assessment (RR 1.64, 95% CI 1.41 to 1.90, 1 study, n = 416, moderate quality of evidence). One trial showed moderate benefit of tacrolimus 0.03% compared with pimecrolimus 1% on the physician's assessment (RR 1.42, 95% CI 1.02 to 1.98, 1 study, n = 139, low-quality evidence), but the effects were equivocal when evaluating BSA. In the comparison of tacrolimus 0.03% with moderate-to-potent corticosteroids, no difference was found in most of the outcomes measured (including physician's and participant's assessment and also for the secondary outcomes), but in two studies, a marginal benefit favouring the corticosteroid group was found for the EASI and BSA scores.Burning was more frequent in those using calcineurin inhibitors than those using corticosteroid tacrolimus 0.03% (RR 2.48, 95% CI 1.96 to 3.14, 5 studies, 1883 participants, high-quality evidence), but no difference was found for skin infections. Symptoms observed were mild and transient. The comparison between the two calcineurin inhibitors (pimecrolimus and tacrolimus) showed the same overall incidence of adverse events, but with a small difference in the fre
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Hay fever, hygiene, and household size.
Strachan, D. P. (1989) · BMJ · doi:10.1136/bmj.299.6710.1259 · Cited by 5,054
Johansson, S. G. O., Bieber, T., Dahl, R., Friedmann, P. S., Lanier, B. Q., Lockey, R. F., Motala, C., Ortega Martell, J. A., Platts-Mills, T. A. E., Ring, J., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.12.591 · Cited by 2,391
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Assessment of the SF-36 version 2 in the United Kingdom.
Jenkinson, C., Stewart-Brown, S., Petersen, S., & Paice, C. (1999) · Journal of Epidemiology and Community Health · doi:10.1136/jech.53.1.46 · Cited by 565
Schmitt, J., von Kobyletzki, L., Svensson, Å., & Apfelbacher, C. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10030.x · Cited by 257
The ISAAC Phase One Study Group, Asher, M. I., Stewart, A. W., Mallol, J., Montefort, S., Lai, C. K., Aït-Khaled, N., & Odhiambo, J. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-8 · Cited by 144
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
European S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18429 · Cited by 289
Emollients and moisturisers for eczema
van Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A. P., & Arents, B. W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012119.pub2 · Cited by 260
Metadata
- Authors
- Cury Martins, J., Martins, C., Aoki, V., Gois, A. F., Ishii, H. A., & da Silva, E. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-07-01
- Volume
- 2016
- Issue
- 10
- Pages
- CD009864-CD009864
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1642860269
- Cited by
- 194
- References
- 8
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical tacrolimus for atopic dermatitis. https://app.cochat.ai/papers/10.1002/14651858.cd009864.pub2
- The paper
- Cury Martins, J., Martins, C., Aoki, V., Gois, A. F., Ishii, H. A., & da Silva, E. M. (2015). Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd009864.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.